Morphological Retrospective Study of Peritoneal Biopsies from Patients with Encapsulating Peritoneal Sclerosis: Underestimated Role of Adipocytes as New Fibroblasts Lineage?
Table 2
Patients with encapsulating peritoneal sclerosis: epidemiological characteristics, diagnostic criteria, risk factors, treatment, and outcomes.
Case EPS 1
Case EPS 2
Case EPS 3
Sex/age at diagnosis (years)
M/19
F/64
F/39
Primitive nephropathy
CAKUT
Diabetes
MPGN
Status at EPS diagnosis
HD
KTx
KTx
Time from peritoneal dialysis arrest to EPS diagnosis (months)
5
18
55
Peritoneal dialysis modality
CAPD
CAPD
CAPD
Time on peritoneal dialysis (months)
21
90
164
Peritonitis episodes ()
3
ND
8
Microorganisms
S. aureus (3)
ND
E. coli (3) S. aureus (3) P. aeruginosa (2)
Glucose overexposure
Yes
No
Yes
Chlorhexidine use
No
No
No
Ciclosporin
No
No
Yes
Everolimus
No
No
Yes
Clinical and radiological diagnostic criteria of EPS
Clinical symptoms/hemoperitoneum
Yes/no
Yes/yes
Yes/yes
Abdominal CT findings
Intestinal subocclusion Adherence
Loculated ascites Peritoneal thickening and calcifications
Loculated severe ascites Peritoneal thickening and calcifications
Treatment of EPS
Azathioprine (mg/day)
50
75
50
Tamoxifen (mg/day)
/
20
10
Dexamethasone (mg/day)
/
32
8
Current state
HD
Died (septicemia)
KTx
Follow-up (months)
237
ND
57
Outcome
Nausea Abdominal pain
ND
Recurrent ascites, bacterial peritonitis (2)
EPS: encapsulating peritoneal sclerosis; M: man; W: woman; CAKUT: congenital abnormality of kidney and urinary tract; MPGN: membranoproliferative glomerulonephritis; HD: haemodialysis; KTx: kidney transplantation CAPD: continuous ambulatory peritoneal dialysis; ND: no data available.
